123 related articles for article (PubMed ID: 38499087)
1. Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023.
Solera JT; Árbol BG; Mittal A; Hall V; Marinelli T; Bahinskaya I; Selzner N; McDonald M; Schiff J; Sidhu A; Humar A; Kumar D
Am J Transplant; 2024 Mar; ():. PubMed ID: 38499087
[TBL] [Abstract][Full Text] [Related]
2. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave.
Solera JT; Árbol BG; Alshahrani A; Bahinskaya I; Marks N; Humar A; Kumar D
Clin Infect Dis; 2022 Dec; 75(12):2193-2200. PubMed ID: 35445690
[TBL] [Abstract][Full Text] [Related]
3. Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave.
Solera JT; Árbol BG; Bahinskaya I; Marks N; Humar A; Kumar D
Am J Transplant; 2023 Jan; 23(1):78-83. PubMed ID: 36148607
[TBL] [Abstract][Full Text] [Related]
4. Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.
Al Jurdi A; Morena L; Cote M; Bethea E; Azzi J; Riella LV
Am J Transplant; 2022 Dec; 22(12):3130-3136. PubMed ID: 35727916
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
[TBL] [Abstract][Full Text] [Related]
7. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
[No Abstract] [Full Text] [Related]
8. Evolving impact of the COVID-19 pandemic on lung transplant recipients: A single-center experience.
Sindu D; Razia D; Bay C; Padiyar J; Grief K; Buddhdev B; Arjuna A; Abdelrazek H; Mohamed H; McAnally K; Omar A; Walia R; Schaheen L; Tokman S
J Heart Lung Transplant; 2024 Mar; 43(3):442-452. PubMed ID: 37852512
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
10. Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
Lee IT; Cosgrove CA; Moore P; Bethune C; Nally R; Bula M; Kalra PA; Clark R; Dargan PI; Boffito M; Sheridan R; Moran E; Darton TC; Burns F; Saralaya D; Duncan CJA; Lillie PJ; San Francisco Ramos A; Galiza EP; Heath PT; Girard B; Parker C; Rust D; Mehta S; de Windt E; Sutherland A; Tomassini JE; Dutko FJ; Chalkias S; Deng W; Chen X; Feng J; Tracy L; Zhou H; Miller JM; Das R;
Lancet Infect Dis; 2023 Sep; 23(9):1007-1019. PubMed ID: 37348519
[TBL] [Abstract][Full Text] [Related]
11. Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.
Tan JY; Wee LE; Tan YH; Conceicao EP; Lim FWI; Chen Y; Than H; Quek JKS; Nagarajan C; Goh YT; Hwang WYK; Phua GC; Chung SJ; Tan TT; Linn YC; Ho AYL; Tan BH
Transpl Infect Dis; 2023 Jun; 25(3):e14024. PubMed ID: 36715661
[TBL] [Abstract][Full Text] [Related]
12. Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data.
Young-Xu Y; Epstein L; Marconi VC; Davey V; Korves C; Zwain G; Smith J; Cunningham F; Bonomo RA; Ginde AA
mBio; 2023 Aug; 14(4):e0102423. PubMed ID: 37535398
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era.
Hedvat J; Lange NW; Salerno DM; DeFilippis EM; Kovac D; Corbo H; Chen JK; Choe JY; Lee JH; Anamisis A; Jennings DL; Codispodo G; Shertel T; Brown RS; Pereira MR
Am J Transplant; 2022 Nov; 22(11):2682-2688. PubMed ID: 35801839
[TBL] [Abstract][Full Text] [Related]
14. Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.
Saharia KK; Husson JS; Niederhaus SV; Iraguha T; Avila SV; Yoo YJ; Hardy NM; Fan X; Omili D; Crane A; Carrier A; Xie WY; Vander Mause E; Hankey K; Bauman S; Lesho P; Mannuel HD; Ahuja A; Mathew M; Avruch J; Baddley J; Goloubeva O; Shetty K; Dahiya S; Rapoport AP; Luetkens T; Atanackovic D
Clin Transl Immunology; 2022; 11(5):e1391. PubMed ID: 35505864
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of severe acute respiratory syndrome coronavirus 2 monoclonal antibodies in high-risk solid organ transplant recipients across three major coronavirus disease 2019 variant waves.
Zeitler K; Piccicacco N; O'Neal M; Montero J; Myers A; Strebig D; Nestler S; Anger LB; Kim K
Transpl Infect Dis; 2023 Aug; 25(4):e14095. PubMed ID: 37378536
[TBL] [Abstract][Full Text] [Related]
16. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
[TBL] [Abstract][Full Text] [Related]
17. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients.
Benotmane I; Velay A; Gautier-Vargas G; Olagne J; Obrecht A; Cognard N; Heibel F; Braun-Parvez L; Keller N; Martzloff J; Perrin P; Pszczolinski R; Moulin B; Fafi-Kremer S; Thaunat O; Caillard S
Am J Transplant; 2022 Nov; 22(11):2675-2681. PubMed ID: 35713984
[TBL] [Abstract][Full Text] [Related]
19. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Lye DC; Tan KB
Lancet Infect Dis; 2023 Jul; 23(7):799-805. PubMed ID: 36924786
[TBL] [Abstract][Full Text] [Related]
20. A single-center review of pre-exposure prophylaxis with tixagevimab-cilgavimab in solid organ transplant recipients.
Morado F; Davoudi R; Kawewat-Ho P; Nanda N; Cartus R; Shaikh SA
Transpl Infect Dis; 2023 Aug; 25(4):e14086. PubMed ID: 37314092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
